ArticleClinical kidney journal2026
Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe kidney involvement.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The RAVE (Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis) and RITUXIVAS (Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis) trials established rituximab (RTX) therapy in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, RAVE excluded patients with severe renal involvement (creatinine >354 µmol/L). Whilst RITUXIVAS did not, treatment included RTX with two cyclophosphamide (CYC) pulses. This study reports outcomes in AAV patients with severe renal involvement treated with RTX alone compared with CYC, together with high-dose steroids. Methods: Data were collected retrospectively for all consecutive AAV presentations with severe renal involvement (peak creatinine >354 µmol/L) between 2010 and 2023 from two renal units. The primary outcome was sustained remission with independent renal function at 12 months. Results: Amongst 107 Conclusion: RTX with steroids is comparable to CYC with steroids for successfully inducing remission in AAV with severe renal involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.